Navigation Links
Generic Growth Strategies
Date:8/15/2013

DUBLIN, August 15, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/fcrtlb/generic_growth) has announced the addition of the "Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

Generic Giants Strategize to Exploit Massive Patent Cliff Potential

Huge rewards and strong competition are prompting generic drug manufacturers to closely examine the best way to maximize market share as the industry patent cliff approaches its peak, states a new report from business intelligence analysts.

According to the firm's latest report, the revenues of drugs subject to patent expiration between 2013 and 2020 are valued at over US$100 billion, offering producers of generics and biosimilars a fantastic opportunity to substantially bolster their own sales.

However, while the next few years hold great promise for these companies, fierce competition exists not only from rival generics manufacturers, but also from major pharmaceutical players looking to maintain market dominance with Authorized Generics' (AG). In response, generics firms are re-evaluating their approach to the market.

Research states that companies such as Hospira are reaching out to new locales in order to build a global presence, while targeting governments looking to bring down healthcare costs. Exploiting pharmaceutically underdeveloped economies may allow generics firms to launch products first, challenging the intellectual property of proprietary pharmaceutical majors.

Generics producers also hope to capitalize on expiring patents by manufacturing complex generics that are difficult to reproduce. These super generics have high barriers to entry, a greater price than most other generics and incur greater Research and Development (R&D) costs; however, there is significant potential for super generics within specific therapeutic areas, such as cancer and conditions involving the central nervous system.

Research expects demand for high-quality generics to increase in the future, as key drugs lose patent protection and governments are offered opportunities to provide vital treatments at significantly reduced costs.

Key Topics Covered:

1.1 List of Tables
1.2 List of Figures

2 Generic Growth Strategies - Introduction

3 Generic Growth Strategies - Market Overview

4 Generic Growth Strategies - Regulatory Landscape

5 Generic Growth Strategies - Major Strategies

6 Generic Growth Strategies - Competitive Landscape

7 Generic Growth Strategies - Conclusion

8 Generic Growth Strategies - Appendix

Companies Mentioned

- Teva Pharmaceutical Industries Limited
- Sandoz
- Mylan
- Watson
- Actavis
- Hospira
- Sanofi
- Daiichi Sankyo
- Aspen
- STADA

For more information visit http://www.researchandmarkets.com/research/fcrtlb/generic_growth

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Launches Generic Version of Zyprexa® Tablets
2. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
3. Mylan Launches Generic Lipitor® in Five European Countries
4. Mylan Launches Generic Version of Plavix® Tablets
5. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
6. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
7. Mylan Launches Generic Version of Viramune® Tablets
8. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy
9. Sihuans First-to-market Generic Drug Roxatidine Passes On-site Inspection for Drug Registration Conducted by the Chinese State Food and Drug Administration
10. Mylan Announces Settlement Agreement in Litigation Relating to its Generic Xopenex®
11. Mylan Launches Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 Celsion Corporation ... development company, today provided an update on its ... clinical trial combining GEN-1, the Company,s DNA-based immunotherapy, ... of newly-diagnosed patients with advanced ovarian cancer who ... surgery.  GEN-1 is an IL-12 DNA plasmid vector ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to ... patients on a global scale. Medical professionals from Europe ... and the US have already signed up for the app, ... totally secure environment. Education  "Imagine a doctor ... a surgeon at Harvard to treat a bomb victim via live ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and raise awareness ... not have access to a toilet, even when they’re on their periods. , WaterAid asked ... hilarious) results help shine a light on the awkwardness that women face while menstruating, even ...
(Date:5/24/2016)... MA (PRWEB) , ... May 24, 2016 , ... ... Harvard Medical School, today announced a licensing relationship that will deliver a new ... This relationship will put the medical knowledge and expertise of Harvard Medical ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and safety labels , has been featured in the National Electrical ... The eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The ...
(Date:5/24/2016)... ... ... After graduating from Cornell, author Joshua Alexander was diagnosed with ... Social Security disability and staying in a group home. In “ Healing Schizoaffective : ... Press), Alexander shares how he was finally able to heal with the help of ...
(Date:5/24/2016)... ... 24, 2016 , ... Design Concepts , a national ... Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was designed working with ... for this often overlooked neighborhood. Located at 609 E. 6th Street, Pueblo’s newest ...
Breaking Medicine News(10 mins):